...on four months of progress toward achieving your treatment goals!
Take a moment to acknowledge all of your hard work and the positive things you've done—both for yourself and for the people you care about.
As you continue to make progress, remember that it's important to stay motivated and to keep setting new goals. One way to
accomplish this is to keep track of how you're doing, day by day, and remember to let your doctor and your counselor know so that they have the information they need to
continue to support your treatment goals.
And, with four months of progress, don't forget to celebrate a little.
| You should know: SUBOXONE Film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and support. |
Keep up the good work:
 | Try these tools to help you stay on track. |
|
| To keep making progress, it's important to have the help you need when you need it. Your Here to Help® tools are designed to help you find what motivates you, set your goals, plan for success, and think about the road ahead, so you can reach your personal treatment goals. We suggest using these tools together and using them often to help you deal with your future hurdles. Put Your Toolbox To Work For You Today |
|
| Find your motivation so you're ready for future challenges. |
|
| Only you know what motivates you to get up in the morning and continue your journey toward your treatment goals. Sometimes motivation can come from your family, your own expectations for a better future, your job, or something else altogether. Find Your Personal
Motivation |
|
| Setting small goals lead you to big results. |
|
| As you probably have experienced after four months of treatment that includes SUBOXONE Film, achieving big goals is accomplished by setting and reaching many smaller ones. To help you with that process, download the Setting Goals Tool and begin. |
With admiration and appreciation—we're here to help.
Take care,
866-973-HERE (4373)
|
|
Important Safety Information
SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) is indicated for maintenance treatment of opioid dependence as part of a complete treatment plan to include counseling and psychosocial support. Treatment should be initiated under the direction of physicians qualified under the Drug Addiction Treatment Act.
SUBOXONE Sublingual Film should not be used by patients hypersensitive to buprenorphine or naloxone.
SUBOXONE Sublingual Film can be abused in a manner similar to other opioids, legal or illicit. Clinical monitoring appropriate to the patient's level of stability is essential.
Chronic use of buprenorphine can cause physical dependence. A sudden or rapid decrease in dose may result in an opioid withdrawal syndrome that is typically milder than seen with full agonists and may be delayed in onset.
SUBOXONE Sublingual Film can cause serious life-threatening respiratory depression and death, particularly when taken by the intravenous (IV) route in combination with benzodiazepines or other central nervous system (CNS) depressants (ie, sedatives, tranquilizers, or alcohol). It is extremely dangerous to self-administer nonprescribed benzodiazepines or other CNS depressants while taking SUBOXONE Sublingual Film. Dose reduction of CNS depressants, SUBOXONE Sublingual Film, or both when both are being taken should be considered.
Liver function should be monitored before and during treatment.
Death has been reported in nontolerant, nondependent individuals, especially in the presence of CNS depressants.
Children who take SUBOXONE Sublingual Film can have severe, possibly fatal, respiratory depression. Emergency medical care is critical. Keep SUBOXONE Sublingual Film out of the sight and reach of children.
Intravenous misuse or taking SUBOXONE Sublingual Film before the effects of full-agonist opioids (eg, heroin, hydrocodone, methadone, morphine, oxycodone) have subsided is highly likely to cause opioid withdrawal symptoms.
Neonatal withdrawal has been reported. Use of SUBOXONE Sublingual Film in pregnant women or during breast-feeding should only be considered if the potential benefit justifies the potential risk. Caution should be exercised when driving vehicles or operating hazardous machinery, especially during dose adjustment.
Adverse events commonly observed with the sublingual administration of SUBOXONE Sublingual Film are numb mouth, sore tongue, redness of the mouth, headache, nausea, vomiting, sweating, constipation, signs and symptoms of withdrawal, insomnia, pain, swelling of the limbs, disturbance of attention, palpitations, and blurred vision.
Cytolytic hepatitis, jaundice, and allergic reactions, including anaphylactic shock, have been reported.
This is not a complete list of potential adverse events associated with SUBOXONE Sublingual Film. Please see full Product Information for a complete list.
To report an adverse event associated with taking SUBOXONE Sublingual Film, please call 1-877-782-6966. You are encouraged to report adverse events of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see full Product information and Medication Guide for Suboxone Film
For more about SUBOXONE Tablet, please see full Product Information
|
|
Unsubscribe | Privacy Promise | Terms of Use | Product Information
If you don't want to get e-mail communications from us in the future, you can opt out.
This communication is sponsored by Reckitt Benckiser and intended for residents of the United States.
SUBOXONE® and Here to Help® are registered trademarks of Reckitt Benckiser Healthcare (UK) Ltd.
SUBOXONE Film is manufactured for Reckitt Benckiser
Pharmaceuticals Inc., Richmond, VA 23235 by
MonoSol RX LLC, Warren, NJ 07059.
Copyright © 2010 Reckitt Benckiser Pharmaceuticals Inc.
Reckitt Benckiser Pharmaceuticals Inc.
10710 Midlothian Turnpike
Richmond, VA 23235-4722
The information in this e-mail is provided for educational and informational purposes only and is not intended as a substitute for direct consultation with a qualified health professional.
|
|
